135 related articles for article (PubMed ID: 38194971)
1. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy.
Cheng S; Han Z; Dai D; Li F; Zhang X; Lu M; Lu Z; Wang X; Zhou J; Li J; Guo X; Song P; Qiu C; Shen W; Zhang Q; Zhu N; Wang X; Tan Y; Kou Y; Yin X; Shen L; Peng Z
Cell Rep Med; 2024 Jan; 5(1):101355. PubMed ID: 38194971
[TBL] [Abstract][Full Text] [Related]
2. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
3. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.
Shimozaki K; Nakayama I; Hirota T; Yamaguchi K
Cells; 2023 Mar; 12(7):. PubMed ID: 37048122
[TBL] [Abstract][Full Text] [Related]
4. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
[TBL] [Abstract][Full Text] [Related]
5. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
6. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
Sillo TO; Beggs AD; Middleton G; Akingboye A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
8. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
9. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C; Auclin E; Alouani E; Mercier M; Hollebecque A; Turpin A; Mazard T; Pernot S; Dutherage M; Cohen R; Borg C; Hautefeuille V; Sclafani F; Ben-Abdelghani M; Aparicio T; De La Fouchardière C; Herve C; Perkins G; Heinrich K; Kunzmann V; Gallois C; Guimbaud R; Tougeron D; Taieb J
Br J Cancer; 2024 Feb; 130(3):442-449. PubMed ID: 38102227
[TBL] [Abstract][Full Text] [Related]
10. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Solomon BL; Garrido-Laguna I
Future Oncol; 2018 Apr; 14(10):947-962. PubMed ID: 29542354
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
[TBL] [Abstract][Full Text] [Related]
12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
13. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract][Full Text] [Related]
17. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.
Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y
Front Immunol; 2021; 12():784336. PubMed ID: 34975873
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
19. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
